Results 201 to 210 of about 82,231 (299)

Challenges and opportunities for oncology drug repurposing informed by synthetic lethality. [PDF]

NPJ Syst Biol Appl
Vermeulen M, Craig AW, Babak T.
europepmc   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Prompt-based multimodal representation learning for drug repurposing. [PDF]

Brief Bioinform
Liu J, U K, Rana D, Meixuan Zhang S, Yu J, Yang S, Jin B, Wang X, Yang Z, Tang H, Zhao J.   +10 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Medicines, Diseases, Indications, and Contraindications (MeDIC): a foundational resource to support drug repurposing. [PDF]

Nucleic Acids Res
DeLuca M, Matentzoglu N, Sharp E, Li J, Hempstead C, Lim M, Kaniewski P, Carter EK, Koirala K, Ding E, Vijnck L, Brokmeier P, Toro S, Schaper K, Vergine J, Li O, Oprea TI, Fajgenbaum DC, Bizon C, Haendel M, Tropsha A.   +20 more
europepmc   +1 more source

Policy Networks and Policy Entrepreneurship in the EU: Explaining Structural Policy Change in Pharmaceutical Innovation Incentives and Health Technology Assessment

European Policy Analysis, EarlyView.
ABSTRACT Policy process research has excelled in explaining structural policy change within national settings, but extensions and applications to the EU level have long proven challenging for scholars. Given that the EU is currently experiencing its longest period of Treaty stability since the 1980s—having evolved into a sui generis political system ...
Vassilis Karokis‐Mavrikos
wiley   +1 more source

Targetable pathways for drug repurposing in gastric cancer. [PDF]

World J Gastroenterol
Valero-Almingol A, Montori S, Felípez N, Santamaría E, Fernandez-Irigoyen J, Luzko I, Cuestas AA, Pardo C, Prat R, Moreira L, Albéniz E.   +10 more
europepmc   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

Epilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source

A genetics-guided integrative framework for drug repurposing: identifying antihypertensive drugs for type 2 diabetes. [PDF]

NPJ Drug Discov
Zhong X, Wei Q, Tiwari A, Wang Q, Tan Y, Chen R, Yan Y, Cox NJ, Li B.   +8 more
europepmc   +1 more source